By: Kristi Rosa From: onclive.com The FDA has approved a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) with hyaluronidase, administered via subcutaneous injection in combination with intravenous chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. The FDA has approved a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) with hyaluronidase-zzxf (Phesgo) for administration via subcutaneous injection …
-
-
Psyching Ourselves Out in a Positive Way as a Breast Cancer Survivor
-
My Home is My Haven for This Breast Cancer Survivor
-
As a Breast Cancer Survivor, There is Nothing Like Doing What You Love
-
The True Meaning of Easter
-
Peace for a Breast Cancer Survivor
